TRANSFUSION MEDICINE PROTOCOLS

Fibrinogen Concentrate - RiaSTAP®

This document should be read in conjunction with the Disclaimer

AIM	To describe the indication, ordering, administration and documentation of Fibrinogen Concentrate - RiaSTAP®
DESCRIPTION	Fibrinogen Concentrate - RiaSTAP® Human Fibrinogen, powder for injection
SPECIFICATIONS	Human fibrinogen is a protein which is important for blood clotting (coagulation). The replacement of human fibrinogen with RiaSTAP® provides an increase in the level of plasma fibrinogen which can temporarily correct the coagulation defect of patients with fibrinogen deficiency. RiaSTAP Product Detail
VIAL SIZE	RiaSTAP® is a freeze dried fibrinogen concentrate derived from human plasma. It contains 1 g of human fibrinogen per vial. Product Information contains information to ensure safe and effective use. The following document is approved by the Therapeutic Goods Administration and made available by CSL. RiaSTAP Product Information
INDICATIONS	**In Australia** The Jurisdictional Blood Committee (JBC) has approved the addition of Fibrinogen Concentrate for patients with congenital fibrinogen deficiency to the list of products funded and supplied under the national blood arrangements administered by the National Blood Authority (NBA).Under NBA arrangements Fibrinogen Concentrate will be available only on a managed basis for the following restricted purpose: *a*) For treatment of acute bleeding (including prophylaxis for high risk patients) in patients with congenital fibrinogen deficiency (including afibrinogenaemia, hypofibrinogenaemia and dysfibrinogenaemia) b) In accordance with management arrangements and oversight by a recognised Haemophilia Treatment Centre

CONSUMER INFORMATION	The Consumer Medicine Information is a leaflet written for people who have been prescribed RiaSTAP® and contains information about the medicine RiaSTAP Consumer Medicine Information
CONSENT	Written consent is required as RiaSTAP® is manufactured from human plasma. Refer to Transfusion Medicine Protocol WNHS Blood Product Prescription, Informed Consent. And Refusal
DOSE	Dosage varies depending on the clinical indication. Refer to Consultant Haematologist/ Consultant Anaesthetist for advice.
ORDERING	RiaSTAP is available at KEMH only on authorisation from either a Consultant Haematologist or a Consultant Anaesthetist. In line with Standard 7 requirements for blood products it is stored and issued from Blood Bank. Contact the Transfusion Medicine Unit (TMU).
ADMINISTRATION	Two staff to perform checks as per the Clinical Practice Manual, WNHS Pharmacy Medication Checking and Administration processes. Check Issue label and patient ID. Check right patient, right product, right dose – prescription matches product supplied. If not identical, contact TMU and prescribing doctor. Refer to RiaSTAP Product Information
OBSERVATIONS	Undertake observations as for all blood products. Vital signs (temperature, pulse, respiration, blood pressure) must be recorded on the observation chart in the medical record. Observe for signs of adverse reactions – Refer to RiaSTAP Product Information
ADVERSE REACTIONS	Any adverse reaction should be reported to the Clinical Haematologist and TMU. Refer to WNHS Management of Transfusion Reactions and Adverse Events, as a guide to further treatment and management of the patient.
DOCUMENTATION	A record should be kept in the patient's history of the following: • The date and time of infusion • Patients observations and condition during the infusion • Amount given • The batch number and expiry date of each bottle used (place a sticker with the batch number on the Transfusion Medicine Record sheet MR735). This information is

	important should the patient have a reaction to the infusion or if there is a need to trace recipients of certain batch numbers at a later date.
For further information, refer to product insert Return product to TMU immediately if no longer required. Product should be used for intended patient (issue label) only.	

References

- RiaSTAP Consumer Medicine Information
-
- RiaSTAP Product Information
- ARCBS Transfusion Medicine Manual is available at www.transfusion.com.au
- National Blood Authority http://www.blood.gov.au/national-product-list
-
- Australian Red Cross Blood Service – Blood products and transfusion practice for health professionals. http://www.transfusion.com.au/blood_products/fractionated_plasma/immunoglobulins
- Flippin' Blood BloodSafe SA / ARCBS Second Edition June 2012 http://resources.transfusion.com.au/cdm/ref/collection/p16691coll1/id/20
- National Safety and Quality Health Service Standards, October 2012. Standard 7: Blood and Blood Products

Related WNHS policies, procedures and guidelines

- WNHS Blood Product Prescription, Consent and Refusal
- WNHS Management of Transfusion Reactions and Adverse Events
- WNHS Pharmacy Medication Checking and Administration
- Neonatology Clinical Care Guidelines
- Obstetrics and Gynaecology Clinical Guidelines
- WNHS Pharmacy Medication Checking and Administration
- Major Haemorrhage and Urgent Transfusion Requests

File path:	WNHS.HAEM.FibrinogenConcentrate

Keywords:	Fibrinogen concentrate, Riastap, Human fibrinogen, major haemorrhage, massive transfusion protocol, major obstetric haemorrhage, plasma derived blood products, plasma immunoglobulins, adverse reactions to blood products, major haemorrhage and urgent transfusion requests		
Document owner:	Chair of KEMH Hospital Transfusion Committee		
Author / Reviewer:	Consultant Haematologist, Scientist in Charge Transfusion Medicine, KEMH Transfusion Coordinator		
Date first issued:	01 01 2005		
Last reviewed:	01 12 2015	Next review date:	01 02 2020
Endorsed by:	KEMH Hospital Transfusion Committee	Date:	01 02 2017
Standards Applicable:	NSQHS Standards: 1 Governance, 5 Patient ID/Procedure Matching, 7 Blood Products		
Printed or personally saved electronic copies of this document are considered uncontrolled. Access the current version from the WNHS website.			